U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
139594
Substance Class Protein
Created
by admin
on Sat Dec 16 11:03:59 UTC 2023
Edited
by admin
on Sat Dec 16 11:03:59 UTC 2023
Protein Type ENZYME
Protein Sub Type CYTOCHROME P450
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
9DX651UO0D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CYTOCHROME P450 1A1
Common Name English
CYTOCHROME P450 FORM 6
Common Name English
CYTOCHROME P450-P1
Common Name English
HUMAN CYTOCHROME P450 1A1
Common Name English
CYP1A1
Common Name English
CYTOCHROME P 450 1A1
Common Name English
0P16S00R2H
Common Name English
Code System Code Type Description
UNIPROT
P04798
Created by admin on Sat Dec 16 11:04:02 UTC 2023 , Edited by admin on Sat Dec 16 11:04:02 UTC 2023
PRIMARY
CAS
329764-85-4
Created by admin on Sat Dec 16 11:04:02 UTC 2023 , Edited by admin on Sat Dec 16 11:04:02 UTC 2023
PRIMARY
FDA UNII
9DX651UO0D
Created by admin on Sat Dec 16 11:04:02 UTC 2023 , Edited by admin on Sat Dec 16 11:04:02 UTC 2023
PRIMARY
PHAROS
P04798
Created by admin on Sat Dec 16 11:04:02 UTC 2023 , Edited by admin on Sat Dec 16 11:04:02 UTC 2023
PRIMARY
Glycosylation Type HUMAN
Glycosylation Link Type Site
O 1_67
Related Record Type Details
Structure of FLORBETABEN F-18
SUBSTRATE -> METABOLIC ENZYME
Structure of MELATONIN
SUBSTRATE -> METABOLIC ENZYME
Structure of ORANTINIB
INDUCER -> METABOLIC ENZYME
Structure of GEFITINIB
INHIBITOR -> METABOLIC ENZYME
Ki
Structure of NINGETINIB
SUBSTRATE -> METABOLIC ENZYME
NINGETINIB M1 FORMATION
MAJOR
Vmax
Structure of ELETRIPTAN
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of MOMELOTINIB
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of TRICLABENDAZOLE
SUBSTRATE -> METABOLIC ENZYME
Structure of LESINURAD
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of PROFENOFOS
INHIBITOR -> METABOLIC ENZYME
Profenofos inhibited CYP1A1/2 activities more than 90%.
Structure of TIVOZANIB
SUBSTRATE -> METABOLIC ENZYME
expressed in extrahepatic tissues such as the lung and intestine, it is unlikely that this isoform would be extensively involved in generating the metabolites observed following incubations with human liver microsomes.
Structure of TROPISETRON
SUBSTRATE -> METABOLIC ENZYME
Structure of LORCASERIN
SUBSTRATE -> METABOLIC ENZYME
Structure of EAPB-0203
SUBSTRATE -> METABOLIC ENZYME
Structure of PHENACETIN
SUBSTRATE -> METABOLIC ENZYME
Structure of CHLORPYRIFOS
INHIBITOR -> METABOLIC ENZYME
Chlorpyrifos inhibited CYP1A1/2 activities more than 90%.
Structure of DEFERASIROX
INHIBITOR -> METABOLIC ENZYME
WEAK
IC50
Structure of OSIMERTINIB
INDUCER -> METABOLIC ENZYME
Modulation of CYP1A1/CYP1A2 levels markedly reduced parent drug concentrations, significantly altering metabolite pharmacokinetics (PK) in humanized mice in vivo. Produces three hydroxy impurities where site is not specified.
Structure of JANEX-1
SUBSTRATE -> METABOLIC ENZYME
Structure of DAPSONE
SUBSTRATE -> METABOLIC ENZYME
Structure of VOXELOTOR
SUBSTRATE -> METABOLIC ENZYME
In vitro metabolism studies involving recombinant enzymes indicated that CYP3A4, CYP1A1, CYP3A5, CYP2C9, CYP2C19 and CYP2B6 were responsible for the oxidative metabolism of voxelotor.
Structure of 5F-203
SUBSTRATE -> METABOLIC ENZYME
Structure of FEBUXOSTAT
SUBSTRATE -> METABOLIC ENZYME
Structure of ANETHOLTRITHION
SUBSTRATE -> METABOLIC ENZYME
Structure of RAMELTEON
SUBSTRATE -> METABOLIC ENZYME
Structure of DIMPYLATE
SUBSTRATE -> METABOLIC ENZYME
Structure of NE-100 FREE BASE
SUBSTRATE -> METABOLIC ENZYME
Structure of PHENTHOATE
INHIBITOR -> METABOLIC ENZYME
Phenthoate inhibited CYP1A1/2 activities more than 90%.
Structure of DACARBAZINE
SUBSTRATE -> METABOLIC ENZYME
Structure of FENITROTHION
INHIBITOR -> METABOLIC ENZYME
Fenitrothion inhibited CYP1A1/2 activities more than 90%
Structure of PIGMENT YELLOW 74
SUBSTRATE -> METABOLIC ENZYME
Structure of 5F-203
INDUCER -> METABOLIC ENZYME
HUMAN BLOOD CELLS
TISSUE EXPRESSION -> PARENT
Structure of INDACATEROL
SUBSTRATE -> METABOLIC ENZYME
Structure of ISTRADEFYLLINE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of TASIMELTEON
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of EAPB-0503
SUBSTRATE -> METABOLIC ENZYME
HUMAN TYPE I COLLAGEN (LUNG)
TISSUE EXPRESSION -> PARENT
Structure of ORANTINIB
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of LUSUTROMBOPAG
INHIBITOR -> TARGET
MINOR
Structure of COPANLISIB
SUBSTRATE -> METABOLIC ENZYME
Structure of MIVOTILATE
ACTIVATOR OF EXPRESSION->TARGET
Structure of Binimetinib
SUBSTRATE -> METABOLIC ENZYME
Structure of RIOCIGUAT
SUBSTRATE -> METABOLIC ENZYME
Structure of CRISABOROLE
SUBSTRATE -> METABOLIC ENZYME
Structure of RISDIPLAM
SUBSTRATE -> METABOLIC ENZYME
Structure of MALATHION
INHIBITOR -> METABOLIC ENZYME
Malathion inhibited CYP1A1/2 activities more than 90%.
Structure of TACRINE
SUBSTRATE -> METABOLIC ENZYME
Structure of DEFERASIROX
SUBSTRATE -> METABOLIC ENZYME
Structure of EXEMESTANE
SUBSTRATE -> METABOLIC ENZYME
Structure of GDC-0339
SUBSTRATE -> METABOLIC ENZYME
Structure of S-16020
SUBSTRATE -> METABOLIC ENZYME
Structure of OSIMERTINIB
SUBSTRATE -> METABOLIC ENZYME
Structure of MAVOGLURANT
SUBSTRATE -> METABOLIC ENZYME
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966